Reply to "Alcohol-related liver disease treatment and EBM"
- PMID: 35727915
- DOI: 10.1111/liv.15342
Reply to "Alcohol-related liver disease treatment and EBM"
Comment on
-
Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines.Liver Int. 2022 Jun;42(6):1330-1343. doi: 10.1111/liv.15221. Epub 2022 Apr 29. Liver Int. 2022. PMID: 35488390 Review.
-
Alcohol-related liver disease treatment and EBM.Liver Int. 2022 Aug;42(8):1909. doi: 10.1111/liv.15336. Epub 2022 Jun 16. Liver Int. 2022. PMID: 35686691 No abstract available.
References
REFERENCES
-
- Louvet A, Trabut JB, Moreno C, et al. Management of alcohol-related liver disease: the French Association for the Study of the liver and the French alcohol society clinical guidelines. Liver Int. 2022;42:1330-1343.
-
- Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-1922.
-
- Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29(10):1155-1160.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical